Daiichi Sankyo breaks ground on $151M cancer drug plant in Shanghai

CAR-T Digest - August 2020

09 September 2025: Daiichi Sankyo breaks ground on $151M cancer drug plant in Shanghai

Daiichi Sankyo has begun building a 1.1 billion yuan ($151 million) facility in Shanghai to manufacture antibody-drug conjugates (ADCs), marking one of the first plants approved under China’s cross-border biotechnology manufacturing pilot
The new site in Pudong will carry out high-value production steps locally, linking Daiichi Sankyo’s global ADC technology with China’s demand and enabling faster patient access to innovative cancer drugs
China’s policy reforms, drug reimbursement improvements and strong biotech infrastructure support the project, encouraging multinational biopharma investment and accelerating regulatory approvals
The facility aims to strengthen supply chains, advance technology with global platforms and quality control, and provide a scalable model for cross-border collaboration
Daiichi Sankyo sees the plant as a key step in integrating its research, production and sales operations in China to broaden treatment access, reinforce its long-term local commitment and support the “Healthy China 2030” initiative